Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CytomX Therapeutics Inc.

    NASDAQ: CTMX · Real-Time Price · USD
    2.48
    -0.27 (-9.82%)
    At close: Jun 16, 2025, 3:59 PM
    2.59
    4.80%
    Pre-market: Jun 17, 2025, 08:52 AM EDT

    CytomX Therapeutics Statistics

    Share Statistics

    CytomX Therapeutics has 157.54M shares outstanding. The number of shares has increased by 2.8% in one year.

    Shares Outstanding

    n/a
    		 157.54M

    Shares Change (YoY)

    n/a
    		 2.8%

    Shares Change (QoQ)

    n/a
    		 2.35%

    Owned by Institutions (%)

    n/a
    		 54.9%

    Shares Floating

    n/a
    		 104.28M

    Failed to Deliver (FTD) Shares

    n/a
    		 191,865

    FTD / Avg. Volume

    n/a
    		 4.06%

    Short Selling Information

    The latest short interest is 18.96M, so 12.04% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 18.96M

    Short % of Shares Out

    n/a
    		 12.04%

    Short % of Float

    n/a
    		 12.5%

    Short Ratio (days to cover)

    n/a
    		 4.36

    Valuation Ratios

    The PE ratio is 2.73 and the forward PE ratio is -6.73. CytomX Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 2.73

    Forward PE

    n/a
    		 -6.73

    PS Ratio

    n/a
    		 0.63

    Forward PS

    n/a
    		 3.6

    PB Ratio

    n/a
    		 -190.73

    P/FCF Ratio

    n/a
    		 -1

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for CytomX Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.25, with a Debt / Equity ratio of -20.58.

    Current Ratio

    n/a
    		 1.25

    Quick Ratio

    n/a
    		 1.25

    Debt / Equity

    n/a
    		 -20.58

    Debt / EBITDA

    n/a
    		 0.35

    Debt / FCF

    n/a
    		 -0.11

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,160,529.41

    Profits Per Employee

    n/a
    		 $267,806.72

    Employee Count

    n/a
    		 119

    Asset Turnover

    n/a
    		 1.15

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 224K

    Effective Tax Rate

    n/a
    		 0.7%

    Stock Price Statistics

    The stock price has increased by 81.02% in the last 52 weeks. The beta is 2.12, so CytomX Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.12

    52-Week Price Change

    n/a
    		 81.02%

    50-Day Moving Average

    n/a
    		 1.56

    200-Day Moving Average

    n/a
    		 1.11

    Relative Strength Index (RSI)

    n/a
    		 55.41

    Average Volume (20 Days)

    n/a
    		 4,723,420

    Income Statement

    In the last 12 months, CytomX Therapeutics had revenue of 138.1M and earned 31.87M in profits. Earnings per share was 0.38.

    Revenue

    n/a
    		 138.1M

    Gross Profit

    n/a
    		 138.1M

    Operating Income

    n/a
    		 25M

    Net Income

    n/a
    		 31.87M

    EBITDA

    n/a
    		 26.76M

    EBIT

    n/a
    		 25M

    Earnings Per Share (EPS)

    n/a
    		 0.38
    Full Income Statement

    Balance Sheet

    The company has 38.05M in cash and 9.38M in debt, giving a net cash position of 28.67M.

    Cash & Cash Equivalents

    n/a
    		 38.05M

    Total Debt

    n/a
    		 9.38M

    Net Cash

    n/a
    		 28.67M

    Retained Earnings

    n/a
    		 -691.58M

    Total Assets

    n/a
    		 98.5M

    Working Capital

    n/a
    		 36.43M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -86.23M and capital expenditures -310K, giving a free cash flow of -86.54M.

    Operating Cash Flow

    n/a
    		 -86.23M

    Capital Expenditures

    n/a
    		 -310K

    Free Cash Flow

    n/a
    		 -86.54M

    FCF Per Share

    n/a
    		 -1.02
    Full Cash Flow Statement

    Margins

    Gross margin is 98.72%, with operating and profit margins of 18.1% and 23.08%.

    Gross Margin

    n/a
    		 98.72%

    Operating Margin

    n/a
    		 18.1%

    Pretax Margin

    n/a
    		 23.24%

    Profit Margin

    n/a
    		 23.08%

    EBITDA Margin

    n/a
    		 18.1%

    EBIT Margin

    n/a
    		 18.1%

    FCF Margin

    n/a
    		 -62.66%

    Dividends & Yields

    CTMX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CTMX is $5, which is 101.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $5

    Price Target Difference

    n/a
    		 101.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -3.28

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist